After announcing the closing of convertible debenture financing on December, 29, 2009, NeurAxon, Inc., a Toronto, ON, Canada-based pharmaceutical company, has been awarded a one-year grant of $267,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
The grant, which was awarded as part of MJFF’s Novel Approaches to Drug Discovery for Parkinson’s Disease 2009 initiative, is designed to fund research to explore neuronal nitric oxide synthase (nNOS) inhibitors as a potential novel treatment paradigm for Parkinson’s disease.
Under the grant, NeurAxon will seek to develop custom-designed, small-molecule, selective nNOS inhibitors. These compounds will be tested for the potential to reduce brain and systemic nitric oxide levels as well as the potential to demonstrate improved neuroprotective properties in in vitro and in vivo preclinical models of Parkinson’s disease.